High-density lipoprotein (HDL) is one of five types of lipoproteins; chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and HDL. Lipoproteins are complex particles that transport lipids, such as phospholipids, triglycerides, and cholesterol, between cells. These lipoproteins classify according to their density and composition. HDL, as per its denomination, is the highest density of the lipoproteins, with the highest proportion of proteins to lipids. HDL is of particular interest in medicine, as research has shown that there is a strong inverse association between HDL cholesterol concentration and the risk of atherosclerosis.
HDL is composed of cholesterol, triglycerides, and various apolipoproteins. In particular, the composition of HDL is apolipoproteins Apo-AI, Apo-AII, Apo-AIV, Apo-AV, Apo-C1, Apo-CII, Apo-CIII, and Apo-E. Apo-AI is the primary structural apolipoprotein of HDL and activates Lecithin–Cholesterol AcylTransferase (LCAT). Apo-AII is also a structural protein in HDL and acts as an activator of hepatic lipase. Apo-IV has an unknown function. Apo-AV activates lipoprotein lipase (LPL), which is responsible for triglyceride lipolysis. Apo-CI is responsible for activating LCAT. Apo-CII is responsible for activating LPL, and Apo-CIII is responsible for inhibiting LPL. Lastly, Apo-E is a ligand for the LDL receptor.
The primary function of HDL is the transport of cholesterol from the peripheral tissues to the liver, playing a role in the biodistribution of lipids. HDL is known for is anti-atherogenic and anti-inflammatory properties. HDL is anti-atherogenic and anti-inflammatory as it uptakes the cholesterol stored in the foam cells of atherosclerotic plaques and returns this cholesterol to the liver, reducing the size of the plaque and its associated inflammation.
HDL synthesis occurs in the liver and the intestines. The first step of HDL synthesis involves the production of its main structural apolipoproteins, Apo-AI. Apo-AI is the structural protein of HDL and receives cholesterol and phospholipids from enterocytes and hepatocytes via transporter ABCA1, forming pre-beta HDL. As HDL travels in the circulation, it also receives free cholesterol and phospholipids from peripheral tissues, chylomicrons, and very-low-density lipoprotein (VLDL). As mentioned, APO-AI acts as a cofactor for LCAT. LCAT converts free cholesterol at the surface of HDL to cholesterol esters, which get incorporated into the cholesterol ester core of HDL.
Cells in peripheral tissues are exposed to and accumulate cholesterol through the circulation and de novo synthesis. However, since most cells can not catabolize cholesterol, they require a reverse transport mechanism to get rid of this cholesterol, which returns cholesterol to the liver. ABCG1 transfers cholesterol in peripheral cells to HDL, like ABCA1 in the liver, and allows the transfer of cholesterol to HDL in the circulation. Subsequently, LCAT incorporates this free cholesterol into the HDL particle and eventually leads to its uptake in the liver through three distinct pathways; the cholesterol ester transfer protein (CETP) pathway, the LDL receptor pathway, and the SR-B1 pathway.
The CETP pathway involves the transfer of lipids between HDL and other lipoproteins. For instance, CETP exchanges the cholesterol esters in the core of HDL particles to Apo-B containing particles, VLDL, and LDL, in exchange for triglycerides. The cholesterol, now contained in VLDL and LDL, can undergo uptake by the LDL receptor, resulting in the return of cholesterol from peripheral tissues to the liver. This exchange also enriches HDL in triglycerides and depletes the cholesterol ester core. As a result, hepatic lipases can metabolize the triglyceride-rich HDL, resulting in small HDL particles. These small HDL particles release their Apo-AI. The liver can then degrade Apo-A1 through an unknown mechanism, or the kidney can clear the free Apo-A1. It is also possible that HDL particles contain Apo-E, which allows HDL particles to undergo uptake by the LDL receptors into the liver and subsequently degraded. Endothelial cell lipase also metabolizes Apo-AI, leading to its clearance from circulation. In brief, the CETP pathway results in both the transfer of cholesterol in HDL to the liver and the elimination of HDL from the circulation through the degradation of Apo-AI.
HDL can also be uptaken by the liver via its apolipoprotein Apo-E. Apo-E interacts with the LDL receptor and leads to the uptake of the entire LDL particle.
The Scavenger receptor class B type 1 (SR-B1) pathway is responsible for the uptake of HDL cholesterol into the liver without the internalization of the HDL particle. After the uptake of cholesterol, the smaller HDL particle gets released back into the circulation. SR-B1 deficiency results in increased HDL levels but correlates with an increased, not decreased, risk of atherosclerosis.
HDL gets tested through blood sampling. It is usually determined as apart of a complete lipid profile. Testing requires that adult patients fast for 12 hours before sampling, whereas testing is possible without fasting in youth without risk factors for heart disease. Without fasting, only total cholesterol and HDL are usable. In this scenario, if the total cholesterol is ≥200 mg/dL or HDL is below 40 mg/dL, the NCEP III guidelines indicate a follow-up lipoprotein profile is necessary for management based on LDL.
A lipid profile, and thus HDL-C, may be ordered for those with risk factors for heart disease, which includes:
For youths, the American Academy of Pediatrics recommends that children be tested once between ages 9 and 11 and repeated between the ages of 17 and 21. This screening is recommended for children under the age of 9 if the children's parents test positive for high cholesterol. The NCEP ATP III guidelines also suggest using agents that will correct the HDL abnormality while also lowering LDL cholesterol, lowering LDL cholesterol being paramount.
To monitor the lipid profile, testing should be completed 4 to 12 weeks after starting a statin and every 3 to 12 months after that to ensure a response. These levels can also get checked after successful lifestyle changes, such as smoking cessation, diet, and exercise. Research has shown that a higher intake of total fat in the form of unsaturated fat can reduce triglycerides and raise HDL cholesterol in the setting of metabolic syndrome.
The ideal lipid profile is controversial. The NCEP ATP III guidelines indicate that the ideal HDL levels should be between 40 and 60 mg/dL.
Some laboratory reports give a ratio of total cholesterol to HDL cholesterol, with a desirable ratio being 5 to 1 and the optimum ratio being 3.5 to 1.
It bears mentioning that lipid profiles should not be measured when a person is acutely ill or is less than six weeks recovering from an illness, as cholesterol t is lowered during acute illness, stress (surgery or trauma), or pregnancy.
The ability of HDL to uptake and return excess cholesterol from peripheral tissues back to the liver is of particular interest because of its role in preventing atherosclerosis, the precursor to myocardial infarction, transient ischemic attack, and stroke. Atherosclerosis generally begins in areas of nonlaminar flow, such as branch points and the inner curvature of arteries. This non-laminar flow increases the shear stress of the artery wall and results in inflammation and activation of the NF-κB pathway. The NF-κB pathway leads to the expression of adhesin molecules, which recruits macrophages to the intima of the artery wall. At the same time, the turbulent flow of the blood in the arteries also leads to the disruption of the tight junctions between the endothelium of the artery, resulting in the deposition of LDL and macrophages. In the intima of the artery, the LDL particles undergo oxidation, which leads to the prolonged activation of the macrophages in the intima and further cascades of inflammation. These macrophages bind and uptake the oxidized LDL, process the LDL cholesterol, and store the cholesterol as cytoplasmic droplets. These cholesterol filled macrophages have a foamy appearance and are called foam cells. Unfortunately, these foam cells remain in the intima of the artery and continue to promote inflammation, increasing the size of the atherosclerotic plaque. Eventually, these atherosclerotic plaques close the lumen of the vessel and lead to symptoms, such as angina. When the plaques eventually rupture, they lead to thrombosis and subsequent occlusion of the artery lumen, resulting in the various cardiovascular events previously mentioned.
HDL is of interest in atherosclerosis as it can extract cholesterol from foam cells and lead to the remission of the atherosclerotic plaque. Specifically, the free cholesterol synthesized in the foam cells is effluxed by ABCA1, SR-B1, and ABCG1 into already circulating HDL or onto Apo-AI or Apo-E discs, forming HDL. In this manner, HDL is considered as an anti-inflammatory, as it removes free cholesterol from foam cells and results in the down-regulation of inflammation within the atherosclerotic plaque. However, it bears mentioning that HDL levels do not always correlate with decreased risk of atherosclerosis, as HDL cholesterol levels can increase in cases where reverse cholesterol transport pathway is reduced, such as SR-B1 deficiency.
Hypoalphalipoproteinemia is a deficiency of high-density lipoprotein. These diseases correlate with a mild increase in triglycerides and are inherited in an autosomal recessive pattern. Defects in the lipid pathways that lead to Hypoalphalipoproteinemia included problems with APOA1, ABCA1 (Tangier disease), and LCAT (Fish Eye Disease). In Tangier disease, functional mutations in ABCA1 reduce the ability of ABCA1 to lipidate newly secreted Apo-AI in the liver and intestines, leading to rapid catabolism and clearance of Apo-A1 and low HDL levels. In mice, an 80% reduction in HDL occurs with ABCA1 knockout in the liver, and a 30% reduction in HDL occurs with ABCA1 knockout in the intestines. In Fish Eye Disease, LCAT deficiency leads to reduced HDL cholesterol and Apo-AI levels, resulting in a higher percentage of small HDL particles but an overall reduction in the level of HDL. In CETP deficiency, humans have high HDL cholesterol levels and large HDL particles. Here, CETP if not able to exchange cholesterol for triglycerides between HDL and VLDL and LDL, leading to the reduced breakdown of HDL and increased HDL size.
HDL levels can increase with lifestyle changes, such as smoking cessation, diet, and exercise.
Also, one study reported a 22% decreased in cardiovascular risk with each 15 mg/dl increase in HDL. However, CETP inhibitors, which can increase HDL levels by 100%, lead to a 60% increase in cardiovascular events. Therefore, the interaction of HDL with cardiovascular risk is a complex one.
|||Ginsberg HN, Lipoprotein physiology. Endocrinology and metabolism clinics of North America. 1998 Sep; [PubMed PMID: 9785050]|
|||Gordon DJ,Probstfield JL,Garrison RJ,Neaton JD,Castelli WP,Knoke JD,Jacobs DR Jr,Bangdiwala S,Tyroler HA, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 Jan; [PubMed PMID: 2642759]|
|||Zhou L,Li C,Gao L,Wang A, High-density lipoprotein synthesis and metabolism (Review). Molecular medicine reports. 2015 Sep; [PubMed PMID: 26082200]|
|||Connelly MA,Shalaurova I,Otvos JD, High-density lipoprotein and inflammation in cardiovascular disease. Translational research : the journal of laboratory and clinical medicine. 2016 Jul; [PubMed PMID: 26850902]|
|||Trigatti BL, SR-B1 and PDZK1: partners in HDL regulation. Current opinion in lipidology. 2017 Apr; [PubMed PMID: 28134663]|
|||Rosenson RS,Brewer HB Jr,Davidson WS,Fayad ZA,Fuster V,Goldstein J,Hellerstein M,Jiang XC,Phillips MC,Rader DJ,Remaley AT,Rothblat GH,Tall AR,Yvan-Charvet L, Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012 Apr 17; [PubMed PMID: 22508840]|
|||Charles MA,Kane JP, New molecular insights into CETP structure and function: a review. Journal of lipid research. 2012 Aug; [PubMed PMID: 22679067]|
|||Shen WJ,Azhar S,Kraemer FB, SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. Annual review of physiology. 2018 Feb 10; [PubMed PMID: 29125794]|
|||Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16; [PubMed PMID: 11368702]|
|||Zmysłowski A,Szterk A, Current knowledge on the mechanism of atherosclerosis and pro-atherosclerotic properties of oxysterols. Lipids in health and disease. 2017 Oct 2; [PubMed PMID: 28969682]|
|||Hu J,Xi D,Zhao J,Luo T,Liu J,Lu H,Li M,Xiong H,Guo Z, High-density Lipoprotein and Inflammation and Its Significance to Atherosclerosis. The American journal of the medical sciences. 2016 Oct; [PubMed PMID: 27776723]|
|||Goldstein JL,Brown MS, The LDL receptor. Arteriosclerosis, thrombosis, and vascular biology. 2009 Apr; [PubMed PMID: 19299327]|
|||Schumacher T,Benndorf RA, ABC Transport Proteins in Cardiovascular Disease-A Brief Summary. Molecules (Basel, Switzerland). 2017 Apr 6; [PubMed PMID: 28383515]|
|||Mabuchi H,Nohara A,Inazu A, Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors. Molecules and cells. 2014 Nov; [PubMed PMID: 25410905]|
|||Kronenberg F, High-density lipoprotein cholesterol on a roller coaster: where will the ride end? Kidney international. 2016 Apr; [PubMed PMID: 26994572]|